Simon H Bridge1, David A Sheridan2, Daniel J Felmlee3, Mary M E Crossey4, Fiona I Fenwick5, Clare V Lanyon6, Geneviève Dubuc7, Nabil G Seidah8, Jean Davignon7, Howard C Thomas4, Simon D Taylor-Robinson4, Geoffrey L Toms5, R Dermot G Neely9, Margaret F Bassendine10. 1. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom. Electronic address: simon.bridge@northumbria.ac.uk. 2. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Institute of Translational & Stratified Medicine, Plymouth University Peninsula School of Medicine & Dentistry, United Kingdom. 3. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Inserm U1110, University of Strasbourg and Center for Liver and Digestive Diseases, Strasbourg University Hospitals, 3 Rue Koeberlé, F-67000 Strasbourg, France. 4. Liver Unit, Department of Medicine, Imperial College London, St Mary's Hospital Campus, Praed Street, London, United Kingdom. 5. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. 6. Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom. 7. Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montréal (IRCM), Montréal, Canada; University of Montréal, Montréal, Canada. 8. Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montréal, Montréal, Canada; University of Montréal, Montréal, Canada. 9. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Clinical Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, United Kingdom. 10. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: margaret.bassendine@newcastle.ac.uk.
Abstract
BACKGROUND & AIMS: Hepatitis C virus (HCV) associates with lipoproteins to form "lipoviral particles" (LVPs) that can facilitate viral entry into hepatocytes. Initial attachment occurs via heparan sulphate proteoglycans and low-density lipoprotein receptor (LDLR); CD81 then mediates a post-attachment event. Proprotein convertase subtilisin kexin type 9 (PCSK9) enhances the degradation of the LDLR and modulates liver CD81 levels. We measured LVP and PCSK9 in patients chronically infected with HCV genotype (G)3. PCSK9 concentrations were also measured in HCV-G1 to indirectly examine the role of LDLR in LVP clearance. METHODS: HCV RNA, LVP (d<1.07g/ml) and non-LVP (d>1.07g/ml) fractions, were quantified in patients with HCV-G3 (n=39) by real time RT-PCR and LVP ratios (LVPr; LVP/(LVP+non-LVP)) were calculated. Insulin resistance (IR) was assessed using the homeostasis model assessment of IR (HOMA-IR). Plasma PCSK9 concentrations were measured by ELISA in HCV-G3 and HCV-G1 (n=51). RESULTS: In HCV-G3 LVP load correlated inversely with HDL-C (r=-0.421; p=0.008), and apoE (r=-0.428; p=0.013). The LVPr varied more than 35-fold (median 0.286; range 0.027 to 0.969); PCSK9 was the strongest negative predictor of LVPr (R(2)=16.2%; p=0.012). HOMA-IR was not associated with LVP load or LVPr. PCSK9 concentrations were significantly lower in HCV-G3 compared to HCV-G1 (p<0.001). PCSK9 did not correlate with LDL-C in HCV-G3 or G1. CONCLUSIONS: The inverse correlation of LVP with apoE in HCV-G3, compared to the reverse in HCV-G1 suggests HCV genotype-specific differences in apoE mediated viral entry. Lower PCSK9 and LDL concentrations imply upregulated LDLR activity in HCV-G3.
BACKGROUND & AIMS:Hepatitis C virus (HCV) associates with lipoproteins to form "lipoviral particles" (LVPs) that can facilitate viral entry into hepatocytes. Initial attachment occurs via heparan sulphate proteoglycans and low-density lipoprotein receptor (LDLR); CD81 then mediates a post-attachment event. Proprotein convertase subtilisin kexin type 9 (PCSK9) enhances the degradation of the LDLR and modulates liver CD81 levels. We measured LVP and PCSK9 in patients chronically infected with HCV genotype (G)3. PCSK9 concentrations were also measured in HCV-G1 to indirectly examine the role of LDLR in LVP clearance. METHODS:HCV RNA, LVP (d<1.07g/ml) and non-LVP (d>1.07g/ml) fractions, were quantified in patients with HCV-G3 (n=39) by real time RT-PCR and LVP ratios (LVPr; LVP/(LVP+non-LVP)) were calculated. Insulin resistance (IR) was assessed using the homeostasis model assessment of IR (HOMA-IR). Plasma PCSK9 concentrations were measured by ELISA in HCV-G3 and HCV-G1 (n=51). RESULTS: In HCV-G3 LVP load correlated inversely with HDL-C (r=-0.421; p=0.008), and apoE (r=-0.428; p=0.013). The LVPr varied more than 35-fold (median 0.286; range 0.027 to 0.969); PCSK9 was the strongest negative predictor of LVPr (R(2)=16.2%; p=0.012). HOMA-IR was not associated with LVP load or LVPr. PCSK9 concentrations were significantly lower in HCV-G3 compared to HCV-G1 (p<0.001). PCSK9 did not correlate with LDL-C in HCV-G3 or G1. CONCLUSIONS: The inverse correlation of LVP with apoE in HCV-G3, compared to the reverse in HCV-G1 suggests HCV genotype-specific differences in apoE mediated viral entry. Lower PCSK9 and LDL concentrations imply upregulated LDLR activity in HCV-G3.
Authors: Germana Grassi; Giorgia Di Caprio; Gian Maria Fimia; Giuseppe Ippolito; Marco Tripodi; Tonino Alonzi Journal: World J Gastroenterol Date: 2016-02-14 Impact factor: 5.742
Authors: Markella V Zanni; Lauren A Stone; Mabel Toribio; Dodie E Rimmelin; Jake Robinson; Tricia H Burdo; Kenneth Williams; Kathleen V Fitch; Janet Lo; Steven K Grinspoon Journal: Open Forum Infect Dis Date: 2017-10-14 Impact factor: 3.835
Authors: Simon H Bridge; Sabrina Pagano; Meleri Jones; Graham R Foster; Dermot Neely; Nicolas Vuilleumier; Margaret F Bassendine Journal: Hepatol Int Date: 2018-02-08 Impact factor: 6.047
Authors: Payal Kohli; Peter Ganz; Yifei Ma; Rebecca Scherzer; Sophia Hur; Bernard Weigel; Carl Grunfeld; Steven Deeks; Scott Wasserman; Rob Scott; Priscilla Y Hsue Journal: J Am Heart Assoc Date: 2016-04-29 Impact factor: 5.501